- Home
- SJM vs EXEL Comparison
SJM vs EXEL Comparison
Compare SJM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJM
- EXEL
- Stock Information
- Founded
- SJM 1897
- EXEL 1994
- Country
- SJM United States
- EXEL United States
- Employees
- SJM N/A
- EXEL N/A
- Industry
- SJM Packaged Foods
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SJM Consumer Staples
- EXEL Health Care
- Exchange
- SJM Nasdaq
- EXEL Nasdaq
- Market Cap
- SJM 11.4B
- EXEL 9.4B
- IPO Year
- SJM N/A
- EXEL 2000
- Fundamental
- Price
- SJM $110.10
- EXEL $36.85
- Analyst Decision
- SJM Buy
- EXEL Buy
- Analyst Count
- SJM 9
- EXEL 18
- Target Price
- SJM $126.78
- EXEL $37.24
- AVG Volume (30 Days)
- SJM 1.2M
- EXEL 2.5M
- Earning Date
- SJM 02-27-2025
- EXEL 02-11-2025
- Dividend Yield
- SJM 3.92%
- EXEL N/A
- EPS Growth
- SJM N/A
- EXEL 170.77
- EPS
- SJM 4.96
- EXEL 1.76
- Revenue
- SJM $8,831,200,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- SJM $9.22
- EXEL $5.36
- Revenue Next Year
- SJM $1.21
- EXEL $10.59
- P/E Ratio
- SJM $22.25
- EXEL $20.87
- Revenue Growth
- SJM 7.76
- EXEL 18.49
- 52 Week Low
- SJM $98.77
- EXEL $20.14
- 52 Week High
- SJM $127.59
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- SJM 61.06
- EXEL 65.59
- Support Level
- SJM $98.77
- EXEL $34.01
- Resistance Level
- SJM $105.53
- EXEL $35.46
- Average True Range (ATR)
- SJM 2.69
- EXEL 1.09
- MACD
- SJM 0.68
- EXEL 0.36
- Stochastic Oscillator
- SJM 93.71
- EXEL 95.70
About SJM The J.M. Smucker Company
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (78% of fiscal 2024 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of Hostess and international (primarily Canada). Retail coffee is its largest category (33% of sales) with brands Folgers and Dunkin'. Pet foods (22% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from consumer foods, primarily peanut butter and jelly, through brands Jif and Smucker's. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.